EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact

Alfredo Mauriello iD, Adriana Correra, Anna Chiara Maratea, Valeria Cetoretta iD, Giovanni Benfari iD, Federica Ilardi iD, Rosangela Cocchia, Matteo Lisi iD, Alessandro Malagoli iD, Giulia Elena Mandoli, Maria Concetta Pastore, Simona Sperlongano und 4 weitere

Journal of Clinical Medicine · 19.01.2026 · 15 (2) · 814

DOI: 10.3390/jcm15020814 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.01.2026. Verfasst von Alfredo Mauriello und 15 weiteren Autor:innen. Beteiligte Einrichtung: S.C. Cardiology, Institute National Cancer, IRCCS, Foundation "G. Pascale", Via M. Semmola 52, 80131 Naples, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs), such as anti-programmed death (PD)-1 and anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 agents, have revolutionized oncology but are associated with immune-related adverse events (irAEs). Among these, ICI-associated myocarditis (ICI-M) is a rare but life-threatening complication, with mortality rates ranging from 27% to 50%.

Objective

This narrative review summarizes the pathogenesis, epidemiology, clinical presentation, diagnostic methods, and management strategies for ICI-induced myocarditis, specifically highlighting emerging biomarkers and immunosuppressive therapeutic approaches. Results and Discussion: ICI-M typically presents within the first 65 days of treatment and is significantly more frequent with combination therapies. Pathologically, it is characterized by myocyte necrosis and massive infiltration of cluster of differentiation (CD)4+ and CD8+ T-cells, often overlapping with myositis (irM/M). Diagnosis relies on a multimodal approach. Management requires immediate ICI cessation and initiation of high-dose corticosteroids as first-line therapy. For steroid-refractory cases, second-line options include mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIG), and emerging therapies like abatacept and ruxolitinib. Rechallenge with ICIs after high-grade ICI-M must be approached with extreme caution by the multidisciplinary team (MDT). Emerging biomarkers and omics techniques hold promise for earlier diagnosis and risk stratification.

Conclusions

ICI-M is a rare yet highly lethal cardiac complication demanding high clinical vigilance and timely diagnosis. Management hinges on an aggressive multidisciplinary approach, aiming to minimize toxicity while balancing oncological efficacy.

Schlagwörter

Stichwörter der Autor:innen

cancercardiotoxicityimmune checkpoint inhibitorsmyocarditis

Autor:innen und Institutionen

  • S.C. Cardiology, Institute National Cancer, IRCCS, Foundation "G. Pascale", Via M. Semmola 52, 80131 Naples, Italy.
  • Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122 Foggia, Italy.
  • Department of Cardiovascular Disease, ASL Napoli 1 Centro, Via Comunale del Principe, 13/a, 80145 Napoli, Italy.
  • Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University Hospital "Ospedali Riuniti", Via Conca 71, 60126 Ancona, Italy.
  • Section of Cardiology, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37100 Verona, Italy.
  • Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University Hospital, Via Pansini 5, 80131 Naples, Italy.

ORCID-Profile: Alfredo Mauriello, Valeria Cetoretta, Giovanni Benfari, Federica Ilardi, Matteo Lisi, Alessandro Malagoli, Matteo Cameli, Antonello D'Andrea

Zitieren

APA

Mauriello, A., Correra, A., Maratea, A. C., Cetoretta, V., Benfari, G., Ilardi, F., Cocchia, R., Lisi, M., Malagoli, A., Mandoli, G. E., Pastore, M. C., Sperlongano, S., Russo, V., Cameli, M., D'Andrea, A., & Working Group of Echocardiography of the Italian Society of Cardiology (2026). Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. Journal of Clinical Medicine, 15(2), 814. https://doi.org/10.3390/jcm15020814

Vancouver

Mauriello A, Correra A, Maratea AC, Cetoretta V, Benfari G, Ilardi F, et al. Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. Journal of Clinical Medicine. 2026;15(2):814. doi:10.3390/jcm15020814

BibTeX
@article{Mauriello2026,
  author = {Mauriello, Alfredo and Correra, Adriana and Maratea, Anna Chiara and Cetoretta, Valeria and Benfari, Giovanni and Ilardi, Federica and Cocchia, Rosangela and Lisi, Matteo and Malagoli, Alessandro and Mandoli, Giulia Elena and Pastore, Maria Concetta and Sperlongano, Simona and Russo, Vincenzo and Cameli, Matteo and D'Andrea, Antonello and Working Group of Echocardiography of the Italian Society of Cardiology, Working Group of Echocardiography of the Italian Society of Cardiology},
  title = {Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {814},
  doi = {10.3390/jcm15020814}
}
Kostenlos starten →